Home›Dicloenac Sodium And Misoprostol›Dicloenac Sodium And Misoprostol + Angiotensin Ii

Does Dicloenac Sodium And Misoprostol Interact with Angiotensin Ii?

CDI records a moderate classification for Dicloenac Sodium And Misoprostol and Angiotensin Ii. The stored summary is: NSAIDs may diminish antihypertensive effect and may result in deterioration of renal function, especially in elderly, volume-depleted, or renally impaired patients. The mechanism involves diminished antihypertensive effect and renal function deterioration. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity
Moderate
Dicloenac Sodium And Misoprostol Class
Prostaglandin E1 Analog
Angiotensin Ii Class
Vasoconstrictor
Management
Monitor for effects
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

Diminished antihypertensive effect and renal function deterioration

What To Tell Your Doctor or Pharmacist

If you are taking Dicloenac Sodium And Misoprostol and your doctor is considering prescribing Angiotensin Ii (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Dicloenac Sodium And Misoprostol(Dicloenac Sodium And Misoprostol Dr)+💊 Angiotensin Ii(Giapreza)

Severity & Interaction Details

🟡
moderate
Be aware — moderate interaction
Documented interaction with manageable risk. May require dose adjustment or monitoring.
Severity scale
MinorContra
On record
Yes
Drug A class
Prostaglandin E1 Analog
Drug B class
Vasoconstrictor
Source
NLP:dicloenac sodium and misoprostol

What this means in plain English

NSAIDs may diminish antihypertensive effect and may result in deterioration of renal function, especially in elderly, volume-depleted, or renally impaired patients.

About Dicloenac Sodium And Misoprostol and Angiotensin Ii

Dicloenac Sodium And Misoprostol is a Prostaglandin E1 Analog, while Angiotensin Ii is a Vasoconstrictor. Angiotensin Ii is also sold under the brand name Giapreza. Dicloenac Sodium And Misoprostol additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:dicloenac sodium and misoprostol

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Dicloenac Sodium And Misoprostol and Angiotensin Ii against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations